Knowledge for motivation. Motivation in Action for health. Dr.Sujnanendra Mishra
Massive” and “Submassive” Replaced by Clinical Categories: The first-ever AHA/ACC clinical practice guideline on acute pulmonary embolism drops a new A-to-E severity classification.
Key Shift:
The guideline abandons “Massive” and “Sub-massive” labels.
Instead, it uses clinical severity categories (A–E) to better stratify risk and guide therapy.
This improves clarity for front-line clinicians and aligns PE care with modern risk-based management.
Preventing and Managing PPH with Long-Acting Oxytocin
SWARAJ Hospital & Research Institute, Bolangir
Published at drsujnanendra.blogspot.com
Carbetocin is a synthetic oxytocin analogue—a long-acting uterotonic agent specifically designed to reduce postpartum hemorrhage. Unlike standard oxytocin, carbetocin provides prolonged uterine tone from a single dose, reducing the need for repeat dosing or continuous infusions.
Evidence: Strongest indication across RCT meta-analyses
Evidence: Mixed by setting; tailored to high-risk populations
WHO-Aligned Implementation: Ideal for challenging settings
Operational Advantage: "One-and-done" bolus replaces bolus + infusion workflows, reducing complexity and infusion errors in busy delivery rooms.
Consistent reduction across studies—fewer escalations needed for hemorrhage control
Lower transfusion rates in cesarean deliveries; reduced Hb drop postoperatively
Single bolus provides prolonged effect—no need for continuous infusion monitoring
Reduces line burden, infusion errors, and nursing resource allocation in delivery settings
⚡ IMPORTANT: Carbetocin has STRONG EVIDENCE for PPH PROPHYLAXIS (prevention before hemorrhage occurs), but its role in TREATMENT of established/active PPH is NOT well-established and may be OFF-LABEL in many regions.
Carbetocin is significantly more expensive than standard oxytocin, which may limit adoption in resource-constrained settings despite WHO recommendations. Cost-effectiveness is context-specific and depends on local pricing.
Most high-level evidence supports prophylaxis only. Use for established PPH is off-label in many regions. Standard second-line agents (misoprostol, ergot alkaloids) remain primary treatment options.
Approval status and indication vary by country/region. Not all health systems have institutional protocols; off-label use requires local endorsement. WHO guidance supports heat-stable variant but adoption remains patchy globally.
Unlike oxytocin infusion, carbetocin provides prolonged effect from one dose—but if PPH is not prevented by that dose, additional escalation to second-line agents is required. Cannot titrate further carbetocin dosing.
Despite heat-stable advantages, global supply remains limited compared to oxytocin. Procurement timelines and import regulations can delay availability in some countries. Not universally stocked in all delivery facilities.
While cesarean-delivery data are robust, evidence for routine use in vaginal birth is less clear. Before–after cohorts show benefit, but large RCTs comparing carbetocin to oxytocin in vaginal delivery are limited.
No significant safety advantage over oxytocin. Class-typical side effects (nausea, flushing, hemodynamic changes) still occur. Does not eliminate need for careful hemodynamic monitoring and management.
For patients with active hemorrhage, carbetocin is NOT recommended as a primary treatment agent. Ergot alkaloids, misoprostol, tranexamic acid, and supportive measures (compression, suturing, interventional radiology) are standard first-line therapy.
Bottom Line on Limitations: Carbetocin is best viewed as a prophylactic upgrade in resource-appropriate settings—especially where cold-chain infrastructure is poor or where reducing additional uterotonics matters clinically. It is NOT a replacement for active PPH management and should not replace established second-line agents in emergency scenarios.
Carbetocin is a powerful, evidence-backed option for PPH prophylaxis—particularly at cesarean and in settings where sustained uterine tone and reduced additional uterotonic requirement matter most. Its heat-stable variant aligns with WHO guidance and supports global maternal health in resource-limited environments.
&nbs
A Clot That Blocks Blood Flow to the Lungs
| Clinical Feature | Points |
|---|---|
| Clinical signs/symptoms of DVT | +3 |
| PE is #1 diagnosis OR equally likely | +3 |
| Heart rate > 100 bpm | +1.5 |
| Immobilization ≥3 days OR surgery in past 4 weeks | +1.5 |
| Prior DVT/PE | +1.5 |
| Hemoptysis | +1 |
| Malignancy (active/treatment within 6 months) | +1 |
⏰ Time is lung. Time is life. Call Rapid Response / Code IMMEDIATELY
| PE Severity | Treatment | Anticoagulation Duration |
|---|---|---|
| Low-risk (hemodynamically stable) |
LMWH / DOAC (Apixaban, Rivaroxaban) |
3–6 months |
| Intermediate-risk (RV strain on echo/troponin+) |
LMWH → DOAC or Warfarin | 3–12 months |
| High-risk/Massive (hypotensive) |
Thrombolysis (tPA) + Anticoagulation |
Minimum 3 months |
| Contraindication to Anticoag | IVC filter (removable) | Until filter removed |
Anticoagulants are NOT optional. Missing doses risks recurrent PE. Take medications exactly as prescribed.
Report black/tarry stools, blood in urine, large bruises, headache, or vomiting immediately.
Gradual return to activity. Avoid prolonged sitting. Walk hourly. Compression stockings reduce post-thrombotic syndrome.
New dyspnea, chest pain, syncope → Go to ER immediately.
Stay mobile, hydrate well, aisle seat. Consider LMWH before long flights (high-risk patients).
20–30 mmHg compression reduces post-thrombotic syndrome risk (swelling, pain).
Source: HER Foundation | Presented by: Swaraj Hospital and Research Institute
Start here for baseline symptoms.
B6/Pyridoxine: 10–25 mg PO (w/ or w/o Doxylamine 10-25 mg) q 6-8 h.
Thiamin/Benfotiamine: 100 mg PO 1-3x/day (Min 250 mg daily PO after 20 weeks).
Prenatal Vitamin: Continue if tolerated, OR change to single vitamins (B1, B9, D with K, Ca, Mg).
Gastric Protection: Add at bedtime with onset of vomiting/poor intake.
Follow this progression if symptoms persist.
1. Add up to 1 from each class:
Antihistamine (discontinue doxylamine)
Dimenhydrinate: 25-50 mg q 4–6 h PO/PR
Diphenhydramine: 25–50 mg PO q 4–6 h
Meclizine or Cyclizine: 25 mg PO q 6-8 h
Dopamine Antagonist (Use 1 at a time or alternate)
Metoclopramide: 2.5-10 mg q 6-8 h PO or ODT
Promethazine: 25 mg q 4-6 h PO or PR
Prochlorperazine: 5-10 mg q 6-8 h PO or 25 mg PR q 12 h
Domperidone: 10-20 mg PO q 6-8 h
2. Add DAILY Bowel Care + Serotonin Antagonists (5-HT3)
Bowel Care: Daily stool softener, magnesium, PEG + stimulant laxative/enema.
Ondansetron: 4-8 mg q 3-6 h PO, ODT, or vaginally (max 32 mg/day) OR
Granisetron: 1 mg q 12 h PO or 3 mg TD patch.
3. Consider Nutrition + Fluids + 1 of the following:
Mirtazapine (15 mg), Methylprednisolone (16 mg, if 9+ weeks), Chlorpromazine (25–50 mg), Olanzapine (5 mg), OR Gabapentin (300-800 mg).
Requires immediate IV intervention.
1. IV Fluids and Dilute Vitamins (Infuse Slowly)
NS or LR + MVI + B1 + B6 + B Complex.
Always give 200 mg B1 IV w/dextrose to prevent WE.
Slowly replace low/marginal electrolytes to prevent ODS.
Always include Thiamin/B1 100-500 mg IV q 8 h daily.
2. If Oral Meds Ineffective/Not Tolerated: Change to 1 of the following with Daily Bowel Care:
Ondansetron: IV (4-8 mg over 15 mins) or SubQ continuous infusion.
Granisetron: 1 mg q 12 h IV or continuous infusion/TD.
3. If Symptoms Continue, add one or both:
Dimenhydrinate or Diphenhydramine: 25-50 mg q 4–6 h IV.
Metoclopramide: IV (2.5–10 mg q 8 h SLOW) or SubQ continuous.
⚠️ Wean IV/SubQ to PO very slowly when stable. Monitor 24 hrs before discharge. Consider enoxaparin for DVT prophylaxis.
Follow arrows to next level of care if symptoms persist. Always wean slowly.
Most medications can cause QT prolongation; consider EKG for high-risk patients.
IM injections are NOT recommended due to muscle atrophy/pain.
Dehydration and nutrient deficiencies decrease treatment response.
Start prophylactic anticoagulation for DVT if immobilized/hospitalized >72 hours.
HELP = HyperEmesis Level Prediction Score.
The definitive treatment of preeclampsia is the delivery of the placenta. The timing of delivery depends on gestational age, the severity of preeclampsia, and maternal and fetal conditions.
Another important aspect in the management of severe preeclampsia is the control of hypertension.
A. BP control
1. Arterial pressure greater than 160/110 mmHg in preeclampsia can increase the risk of complications, and it should be controlled.
2. BP control should only be done in the ICU, preferably with arterial line monitoring.
3. BP control should also be done along with fetal monitoring. Avoid sudden falls in BP as it can result in fetal distress.
4. The goal of BP control is a 15–25% reduction in the mean arterial pressure, and a reduction of pressure to baseline BP levels (<140/90 mmHg) rather than normal BP, should be avoided as it may compromise placental perfusion.
5. Drugs
a) Labetalol (IV 20 mg) can be given initially, followed by doubling the dose every 10 min to a cumulative dose of 300 mg. This drug can result in severe bradycardia. A continuous infusion of labetalol at a rate of 0.5–2 mg/min can also be used.
b) Hydralazine (5–10 mg) can be given every 20 min (maximum of 40 mg) until BP is controlled.
c) Nifedipine or nicardipine can be given (sudden precipitous decrease in BP or tachycardia can occur).
d) Intravenous nitroglycerin (10–100 mg/min) or sodium nitroprusside (2–8 mg/min) can be given. Prolonged use of nitroglycerin may lead to methemoglobinemia. Cyanide toxicity in the mother and fetus may occur with sodium nitroprusside, limiting its use to less than 4 h and only as a last resort.
B. Seizure control
1. The initial management of eclampsia includes airway, breathing, and circulation.
2. Seizure prophylaxis is given intrapartum or postpartum with magnesium sulfate in cases of severe preeclampsia.
3. The initial bolus of magnesium (4 g over 5–15 min) is followed by an infusion of 1–2 g/h maintained for 24 hrs.
4. The mechanism of action of magnesium is unknown, but magnesium suppresses excitatory neurotransmitter release by replacing calcium at nerve endings.
a) Monitor toxicity—loss of deep tendon reflexes; loss of patellar reflex occurs when the plasma magnesium level is more than 10 mg%. Look for respiratory muscle weakness.
b) Magnesium has a relatively narrow therapeutic range, and target magnesium serum concentrations are 5–8 mg/dL.
c) Infusion dose should be reduced in cases of renal dysfunction. Serum magnesium levels should be monitored every 4–6 hours and whenever a seizure occurs, or signs of toxicity are present, as per Table
|
Clinical manifestations related to the serum concentration of magnesium |
|
|
Serum magnesium levels (mg/dL) |
Effects |
|
5–8 |
Therapeutic |
|
8–12 |
Loss of deep tendon reflexes |
|
12–16 |
Muscular paralysis and respiratory difficulties |
|
>17 |
Conduction disturbances |
|
>25 |
Cardiac arrest |
d) In recurrent seizures, an additional 2–4 g of magnesium sulfate can be given over 5 mins concurrently with the magnesium sulfate infusion.
e) Calcium gluconate 15–30 mL of a 10% solution, administered intravenously over 2–5 minutes, is given to women with cardiac arrest or severe cardiac toxicity related to magnesium toxicity.
f) If seizures are not controlled by a repeat magnesium bolus, then diazepam or lorazepam can be administered.
g) Discontinue magnesium sulfate 24 h after delivery.
C. Fluid management
1. Despite peripheral edema, patients with preeclampsia are volume-depleted with high peripheral vascular resistance. Diuretics should be avoided.
2. Aggressive volume resuscitation, on the other hand, may lead to pulmonary edema, which is a common cause of maternal morbidity and mortality. Because volume expansion has no demonstrated benefit, patients should be fluid-restricted, when possible, at least until the period of postpartum diuresis.
3. Central venous or pulmonary artery pressure monitoring or other hemodynamic monitoring modalities may be indicated in critical cases.
4. Careful measurement of fluid input and output is advisable, particularly in the immediate postpartum period.
5. D. Decide the timing and type of delivery
6. As maternal morbidity is very high with severe preeclampsia, prompt delivery is indicated regardless of gestational age.
7. Women with severe preeclampsia who are managed expectantly (non-severe disease) must be delivered under the following circumstances:
a. Severe hypertension develops refractoriness to treatment
b. Non-reassuring fetal heart status
c. Uncontrollable BP
d. Oligohydramnios, with amniotic fluid index of less than 5 cm.
e. Severe intrauterine growth restriction.
f. Oliguria (<500 mL/24 h)
g. Serum creatinine level of at least 1.5 mg/dL
h. Pulmonary edema
i. Shortness of breath or chest pain with pulse oximetry of <94% on room air
j. Headache that is persistent and severe Right upper quadrant tenderness with deteriorating liver function test
k. Development of HELLP syndrome
l. Severe hypertension after 34 weeks when their blood pressure has been controlled and a course of corticosteroids has been completed (if appropriate).
m. Offer birth to women with pre-eclampsia before 34 weeks only after discussion with neonatal and anesthetic teams and a course of corticosteroids has been given.
n. Preeclampsia is not an indication for caesarian delivery and many patients can have a normal vaginal delivery.
Watch for complications
1. Abruptio placentae
2. Disseminated intravascular coagulopathy (DIC)
3. Renal insufficiency and acute renal failure
4. HELLP syndrome
5. Eclampsia
6. Cerebral hemorrhage
7. Fetal changes—intrauterine growth restriction, abruptio placentae, oligohydramnios
8. Intrauterine fetal death
Managing Complications
HELLP syndrome
1. HELLP syndrome can complicate 4–12% of patients with severe preeclampsia.
2. Signs and symptoms are right upper quadrant or epigastric pain, nausea and vomiting, malaise, and nonspecific viral-like symptoms. Physical examination findings include right upper quadrant or epigastrium tenderness and generalized edema.
Tennessee classification:
1. Hemolysis: established by the presence of at least two of the following:
2. Peripheral smear showing schistocytes and burr cells
3. Serum bilirubin ≥1.2 mg/dL
4. Low serum haptoglobin (≤25 mg/dL) or LDH ≥2 times the upper level of normal
5. Severe anemia unrelated to blood loss, Elevated liver enzymes Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the upper level of normal, Low platelets: <100,000 cells/microL
Delivery is the definitive treatment for HELLP syndrome.
a. Delivery is indicated for women with HELLP syndrome at greater than 34 weeks of gestation.
b. During labor and for 24-h postpartum, patients should receive intravenous magnesium sulfate for seizure prophylaxis.
c. If gestation is less than 34 weeks, delivery may be delayed for 48 hours to administer a steroid course of either betamethasone (12 mg intramuscular every 24 hours for two doses, with delivery 24 hours after the last dose) or dexamethasone (6 mg intramuscular every 12 hours for 2 days).
d. Platelets are generally transfused when the platelet count is less than 20,000/mm. For cesarean delivery or with any significant bleeding, platelets should be transfused if the platelet count is less than 50,000/mm3.
Acute Pulmonary Edema
1. Management is similar to non-pregnant patients.
2. Intravenous furosemide (bolus 20–40 mg over 2 min) is used to promote diuresis. Repeated doses of 40–60 mg is given after 30 min or infusion if there is an inadequate diuretic response (maximum dose 120 mg/h).
3. Careful fetal monitoring, fluid restriction, and strict fluid balance and positioning
